B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.

B-cell regeneration hemodilution immunophenotyping measurable residual disease multiple myeloma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Apr 2021
Historique:
received: 08 02 2021
revised: 27 03 2021
accepted: 29 03 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19

Identifiants

DOI: 10.3390/cancers13071704 PMID: 33916787 PMC: PMC8038337
pubmed: 33916787
pii: cancers13071704
doi: 10.3390/cancers13071704
pmc: PMC8038337
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489, CB16/12/00480
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES/DGPU)
ID : 000281/2016-06
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES-PROEX)
ID : 641/2018
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico of Brazil (CNPQ)
ID : 400194/2014-7
Organisme : Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro of Brazil (FAPERJ)
ID : E26/110.105/2014, E26/102.191/2013 and E01/200/537/2018

Références

Br J Haematol. 2011 Nov;155(4):509-11
pubmed: 21539533
Biol Blood Marrow Transplant. 2014 Jun;20(6):896-9
pubmed: 24631739
Nat Immunol. 2004 Feb;5(2):133-9
pubmed: 14749784
Leuk Res. 2001 Jul;25(7):563-70
pubmed: 11377681
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Haematologica. 2017 May;102(5):922-931
pubmed: 28126960
Blood. 2002 Mar 1;99(5):1853-6
pubmed: 11861305
Am Soc Clin Oncol Educ Book. 2018 May 23;38:e6-e15
pubmed: 30231373
Cytometry B Clin Cytom. 2009 Jan;76(1):18-26
pubmed: 18942105
Blood. 2016 Jun 23;127(25):3165-74
pubmed: 27118453
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861548
Leuk Res. 2012 Nov;36 Suppl 1:S3-12
pubmed: 23176722
Bone Marrow Transplant. 2017 Jun;52(6):832-838
pubmed: 28368375
Tissue Antigens. 2008 Jan;71(1):57-66
pubmed: 18005092
Nature. 2010 Jan 28;463(7280):495-500
pubmed: 20110993
Immunity. 2004 Jun;20(6):707-18
pubmed: 15189736
Blood. 1998 May 1;91(9):3518-23
pubmed: 9558413
Eur J Cancer. 2016 Nov;67:21-37
pubmed: 27592069
Leukemia. 2011 Apr;25(4):697-706
pubmed: 21252988
Haematologica. 2008 Mar;93(3):431-8
pubmed: 18268286
J Immunol Methods. 2017 Mar;442:54-58
pubmed: 28041941
Nat Rev Immunol. 2006 Oct;6(10):741-50
pubmed: 16977339
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Blood. 1996 Apr 15;87(8):3375-83
pubmed: 8605355
Int J Lab Hematol. 2020 Aug;42(4):e192-e195
pubmed: 32449827
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Clin Cancer Res. 2016 Nov 15;22(22):5453-5460
pubmed: 28151713
Cytometry B Clin Cytom. 2010;78 Suppl 1:S47-60
pubmed: 20839338
Blood Rev. 2015 Nov;29(6):387-403
pubmed: 26094881
Br J Haematol. 1998 Jan;100(1):176-83
pubmed: 9450807
J Clin Oncol. 2017 Sep 1;35(25):2900-2910
pubmed: 28498784
Exp Hematol. 2005 Dec;33(12):1500-7
pubmed: 16338493
Leukemia. 2017 Oct;31(10):2094-2103
pubmed: 28104919
N Engl J Med. 2004 Oct 28;351(18):1860-73
pubmed: 15509819
Haematologica. 1998 Dec;83(12):1069-75
pubmed: 9949623
Blood Adv. 2017 Jun 20;1(15):1056-1066
pubmed: 29296748
Front Immunol. 2014 Jun 03;5:257
pubmed: 24917865
Haematologica. 2013 Jul;98(7):1142-6
pubmed: 23645688
Haematologica. 2013 Jan;98(1):79-86
pubmed: 22773604
Cancer Res. 2016 Oct 1;76(19):5597-5601
pubmed: 27634765
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Am J Clin Pathol. 2009 Nov;132(5):728-32
pubmed: 19846814
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
Cytometry B Clin Cytom. 2016 Jan;90(1):31-9
pubmed: 25619868
Br J Haematol. 2017 Jul;178(2):267-278
pubmed: 28542787
Blood Rev. 2014 Mar;28(2):75-86
pubmed: 24582081
Am J Pathol. 1996 Nov;149(5):1493-9
pubmed: 8909239
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Leukemia. 2016 Mar;30(3):526-35
pubmed: 26265184
Clin Infect Dis. 2009 Oct 15;49(8):1211-25
pubmed: 19769539
Mayo Clin Proc. 2016 Jan;91(1):101-19
pubmed: 26763514
Blood. 1998 Apr 15;91(8):2731-6
pubmed: 9531582

Auteurs

Robéria Mendonça de Pontes (R)

Internal Medicine Postgraduate Program, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
Cytometry Service, Institute of Paediatrics and Puericultura Martagão Gesteira (IPPMG), Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-912, Brazil.
ORCID: 0000-0003-3608-8254

Juan Flores-Montero (J)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
ORCID: 0000-0002-1119-4387

Luzalba Sanoja-Flores (L)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Institute of Biomedicine of Seville, Department of Hematology, University Hospital Virgen del Rocío of the Consejo Superior de Investigaciones Científicas (CSIC), University of Seville, 41013 Seville, Spain.
ORCID: 0000-0002-9275-7793

Noemi Puig (N)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.

Roberto J Pessoa de Magalhães (RJ)

Department of Internal Medicine, University Hospital Clementino Fraga Filho, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.

Alba Corral-Mateos (A)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.

Anna Beatriz Salgado (AB)

Internal Medicine Postgraduate Program, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.

Omar García-Sánchez (O)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.

José Pérez-Morán (J)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.

Maria-Victoria Mateos (MV)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.
ORCID: 0000-0003-2390-1218

Leire Burgos (L)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Clínica Universidad de Navarra, 31008 Pamplona, Spain.

Bruno Paiva (B)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Clínica Universidad de Navarra, 31008 Pamplona, Spain.

Jeroen Te Marvelde (J)

Department of Immunology, Erasmus MC, (EMC) University Medical Center Rotterdam, 3015 GA Rotterdam, The Netherlands.

Vincent H J van der Velden (VHJ)

Department of Immunology, Erasmus MC, (EMC) University Medical Center Rotterdam, 3015 GA Rotterdam, The Netherlands.

Carlos Aguilar (C)

Department of Hematology, Hospital General de Santa Bárbara, 42005 Soria, Spain.
ORCID: 0000-0002-5225-6687

Abelardo Bárez (A)

Department of Hematology, Complejo Asistencial de Ávila, 05071 Ávila, Spain.
ORCID: 0000-0001-8982-6105

Aranzazú García-Mateo (A)

Department of Hematology, Complejo Asistencial de Segovia, 40002 Segovia, Spain.

Jorge Labrador (J)

Department of Hematology and Research Unit, Hospital Universitario de Burgos, 09006 Burgos, Spain.
ORCID: 0000-0002-3696-0287

Pilar Leoz (P)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.

Carmen Aguilera-Sanz (C)

Department of Hematology, Hospital El Bierzo, 24404 Ponferrada, Spain.

Brian Durie (B)

Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA 90048, USA.

Jacques J M van Dongen (JJM)

Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Angelo Maiolino (A)

Internal Medicine Postgraduate Program, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
Department of Internal Medicine, University Hospital Clementino Fraga Filho, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
Americas Centro de Oncologia Integrado, Rio de Janeiro 22290-030, Brazil.

Elaine Sobral da Costa (E)

Internal Medicine Postgraduate Program, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
Cytometry Service, Institute of Paediatrics and Puericultura Martagão Gesteira (IPPMG), Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-912, Brazil.

Alberto Orfao (A)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
ORCID: 0000-0002-0007-7230

Classifications MeSH